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preferences questionnaire was elaborated in a pilot study: treat-
ment mode of administration, time spent in hospital for admin-
istration, immediate toxicity, and level of symptoms control;
distributed in 9 hypothetic scenarios. Second line NSCLC
patients were asked to score by preferred scenario, through the
conjoint analysis method. Socio-demographic, clinical and
health-related quality of life (RSCL) characteristics were col-
lected and linear regression models were performed. RESULTS:
A total of 172 patients were enrolled. Mean (SD) age 61.9 (10.5)
years. Seventy-ﬁve percent were men, 84.8% in NSCLC stage IV,
50% ECOG 1 20.3% of patients received cisplatine +
gemcitabine in ﬁrst line, 30.8% showed treatment’s adverse reac-
tions and 52.9% were scheduled to erlotinib as second line.
Psychological symptoms’ was the most affected RSCL dimension.
The ICC of questionnaire’s scenarios was assessed (0.55–
0.88).The most preferred attribute was symptoms’ control and
the most preferred scenario was: oral administration, no time
spent in hospital, low toxicity and total symptoms’ control (G
scenario). Patients who started oral administration vs patients
who started intravenous administration, gave more utility/
importance to the attributes ‘treatment administration’ (0.30 vs
-0.12) and ‘time spent in hospital’ (0.62 vs 0.45). Psychological
and daily functioning affection, ECOG 1-2 and adverse reactions
in ﬁrst line were related to G scenario. CONCLUSIONS: The
most valued attributes by advanced NSCLC patients are
moderate-total symptoms’ control and oral administration.
Patients with worst functional status and psychological affection
preferred total symptoms’ control, oral administration, no time
spent in hospital and low toxicity. Treatment preference’s ques-
tionnaire showed utility, feasibility and reliability for treatment
decisions, allowing physicians to explore patients’ preferences
before initiating treatment.
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OBJECTIVES: To evaluate whether shared decision making
in treatment selection for cancer differs by race. METHODS:
Newly diagnosed local stage prostate cancer patients and their
family members were recruited following biopsy but prior to
initiating treatment at urology practices in three states to partici-
pate in a take-home survey. RESULTS: A total of 192 family
pairs completed surveys. In 14% of the family pairs, at least one
subject was black, 13% had a Hispanic member, and 66% had
no minority members. Discussions between patients and family
members about treatment options occurred “very” often among
26% of black families, 30% of Hispanic families, 52% of white
families (p = 0.06). Patients reported differences by race in how
extensively physicians involved them (60% among blacks, 79%
among Hispanics, and 49% among whites, p = 0.04). 91% of
family members reported attending physician visits with the
patient; 66% indicated their role was to help the patient make a
treatment choice, 72% reported the physician involved them in
the decision process, and 61% reported “excellent” satisfaction
with the patient’s doctor with no signiﬁcant differences by race.
In multivariate analyses, family members who perceived that the
patient’s physician did not involve them were signiﬁcantly less
likely to be highly satisﬁed (OR = 0.22, 95% CI 0.10–0.48).
CONCLUSIONS: Family members of all races often attended
clinic visits and discussed treatment options with physicians.
Compared to whites, black and Hispanic patients, but not family
members, reported more encouragement by physicians to be
involved in the decision process. Black and Hispanic families
were less likely to discuss treatment options among themselves.
Family member satisfaction was dependent on their perception of
whether the physician involved them in the decision process.
Race may be less of a factor when physicians involve patients and
family members extensively in the treatment decision making
process.
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OBJECTIVES: “Domiciliary palliative care ‘OKAYAMA’ model”
in which specialist palliative care team cooperates with primary
care team, is attracting attention to promote a home palliative
care service in Japan. To evaluate the outcome of this
“OKAYAMA model”, we investigated the satisfaction of the
patients’ family who received the home palliative care service by
this model. METHODS: A survey form consisting of 20 items
from the FAMCARE Scale was then sent to 83 surviving family
members of patients who had received care under this
“OKAYAMA” palliative care model. The study plan was
reviewed and approved by an ethics committee. RESULTS: The
mean score for the survey was 3.94  0.19 points (out of a
possible 5). Responses of “satisﬁed” or better were received by
more than 50% of respondents for nearly all items. The ratings
were high for “pain relief,” “answers from health professionals,”
“availability of doctors to the family,” “doctor’s attention to the
patient’s description of symptoms,” and “availability of the
doctor to the patient.” A positive assessment was made for time
spent and efforts made to respond to the desires of patients’
families following the conclusion of pain control prior to home
palliative care. Conversely, issues remain in items such as “avail-
ability of a hospital bed.” Four factors were identiﬁed in a factor
analysis of the FAMCARE Scale: “adequate amount of informa-
tion,” “attitude of medical personnel,” “education and support
system for families,” and “emergency responses.” Only 44% of
respondents were satisﬁed with the care provided by the respon-
dents themselves as a family member, suggesting the need for
environmental improvements to ease the burden on families.
CONCLUSIONS: The results of this study help us to develop an
appropriate model for a home palliative care system using a
multidisciplinary team approach.
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OBJECTIVES: To elicit treatment preference and WTP for Meth-
ylnaltrexone, a novel peripheral opioid antagonist versus existing
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